The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

In New York, skylights are a coveted design feature. These examples double as functional works of art. By Craig Kellogg and Ashok Sinha A loft in a 19th-century warehouse, a four-bedroom house in ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Take a look back at all our House of the Month winners, and choose your House of the Year winner by voting in our poll. Some developers who tried to emulate the pricey high-rises of New York and Miami ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Gordon Scott has been an active investor and technical analyst or ...

On Dec. 20, 1989, the United States invaded Panama with 26,000 troops. They destroyed 20,000 homes. They killed hundreds of innocent people. Panamanian citizens will not forget and they still demand ...

The talk/variety series “Real Time with Bill Maher,” hosted by Bill Maher, has been running for nearly two decades now, and is showing no signs of slowing down. In fact, HBO has already renewed the ...

REITs pay out dividends; real estate funds can appreciate in value Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...